Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs as a possible treatment for
Hepatocellular Carcinoma or Biliary Tract Cancer.
The interventions involved in this study are:
- Durvalumab
- Tremelimumab
- Radiation Therapy